Related Experiment Video

Updated: Mar 17, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

Rebecca Christine Feiner¹, Kristian Mark Müller¹

¹a Cellular and Molecular Biotechnology group, Faculty of Technology , Bielefeld University , Bielefeld , Germany.

Expert Review of Proteomics

|July 19, 2016

Abstract

Introduction:

Epidermal growth factor receptor (EGFR) expression is upregulated in many tumors and its aberrant signaling drives progression of many cancer types. Consequently, EGFR has become a clinically validated target as extracellular tumor marker for antibodies as well as for tyrosine kinase inhibitors. Within the last years, new mechanistic insights were uncovered and, based on clinical experience as well as progress in protein engineering, novel bio-therapeutic approaches were developed and tested.

Areas Covered:

The potential therapeutic targeting arsenal in the fight against cancer now encompasses bispecific or biparatopic antibodies, DARPins, Adnectins, Affibodies, peptides and combinations of these binding molecules with viral- and nano-particles. We review past and recent binding proteins from the literature and include a brief description of the various targeting approaches. Special attention is given to the binding modes with the EGFR. Expert commentary: Clinical data from the three approved anti EGFR antibodies indicate that there is room for improved therapeutic efficacy. Having choices in size, affinity, avidity and the mode of EGFR binding as well as the possibility to combine various effector functions opens the possibility to rationally design more effective therapeutics.

Insights

Novel bio-therapeutics targeting the epidermal growth factor receptor (EGFR) are being developed. These advanced approaches, including engineered proteins and nanoparticles, aim to improve cancer treatment efficacy by optimizing EGFR targeting strategies.

Area of Science:

Oncology
Molecular Biology
Biotechnology

Background:

Epidermal growth factor receptor (EGFR) is overexpressed in numerous cancers, driving tumor progression.
EGFR is a validated target for antibody and tyrosine kinase inhibitor therapies.
Recent advances in protein engineering and mechanistic insights have spurred the development of novel therapeutic strategies.

Purpose of the Study:

To review emerging bio-therapeutic approaches targeting EGFR.
To discuss various protein-based binding molecules and their engineering.
To highlight novel strategies for enhancing therapeutic efficacy against EGFR-expressing cancers.

Main Methods:

Literature review of past and recent binding proteins targeting EGFR.
Analysis of different targeting strategies, including bispecific antibodies, DARPins, Adnectins, Affibodies, and peptides.
Examination of combinations with viral and nanoparticles for enhanced delivery and function.

Main Results:

A diverse array of novel binding molecules and targeting platforms are available for EGFR.
Various binding modes and protein engineering approaches offer tailored strategies for EGFR engagement.
Combinatorial approaches with nanoparticles present new avenues for improved therapeutic outcomes.

Conclusions:

Existing anti-EGFR therapies show potential for improvement, as indicated by clinical data.
The variety of targeting molecules, binding affinities, and effector functions allows for rational design of more effective therapeutics.
Future cancer therapies can leverage these advanced bio-therapeutics for enhanced efficacy and specificity against EGFR-driven tumors.

Read full analysis

Keywords:

EGF-R ErbB1 antibody antigen-binding scaffolds cancer targeting tumor targeting virus-like particles

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...

Protein Networks

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Articles linked to this work by shared authors, journal, and citation graph.

Towards effective cystic fibrosis gene therapy by optimizing prime editing and pulmonary-targeted LNPs.

Frontiers in systems biology·2025

See all related articles